TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28776105

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention delivered by Maternal and Child Health Nurses (MCHNs), n = 20
Number of subjects: 541

Group type: COMPARATOR
Intervention: Routine Care, n = 20
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 541
Study: 25993251

Group type: EXPERIMENTAL
Intervention: Hyrax appliance
Number of subjects: 33

Group type: COMPARATOR
Intervention: Haas appliance
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pre-expansion to post-expansion root volumes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Percentage of root volume loss
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Volumetric changes after 6 months of retention
Number of subjects: 33
Study: 24338901

Group type: EXPERIMENTAL
Intervention: 3D T2prep-GRE
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D spin-echo EPI
Number of subjects: 0
Study: 21134950

Group type: EXPERIMENTAL
Intervention: Maximal multi-faceted strategy (professional and patient oriented)
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Minimal professional-oriented implementation strategy (audit and feedback)
Number of subjects: 1499
Study: 18951682

Group type: EXPERIMENTAL
Intervention: Cooling
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cooling (early group)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cooling (longer group)
Number of subjects: 111
Study: 17230055

Group type: EXPERIMENTAL
Intervention: Physiogel AI cream
Number of subjects: 0
Study: 14715560

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 67
Study: 11248824

Group type: EXPERIMENTAL
Intervention: Ofloxacin 0.3% ophthalmic solution
Number of subjects: 217

Group type: COMPARATOR
Intervention: Ciprofloxacin 0.3% ophthalmic solution
Number of subjects: 217
Study: 9215245

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate Diskhaler
Number of subjects: 217
Study: 7517181

Group type: EXPERIMENTAL
Intervention: Low dose aspirin 75 mg
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 3691943

Group type: EXPERIMENTAL
Intervention: Multispatula
Number of subjects: 236

Group type: COMPARATOR
Intervention: Ayre spatula
Number of subjects: 236
Study: 31863505

Group type: EXPERIMENTAL
Intervention: Xylazine (0.1 or 0.2 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acepromazine (0.02 or 0.04 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Local analgesia (4 mL 2% mepivacaine administered subcutaneously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Intravenous saline (1 mL)
Number of subjects: 6
Study: 30219460

Group type: EXPERIMENTAL
Intervention: Dance Therapy (DT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Support group (control)
Number of subjects: 13
Study: 26728931

Group type: EXPERIMENTAL
Intervention: Client-centred and activity-oriented intervention program
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 24178750

Group type: EXPERIMENTAL
Intervention: IV G‐CSF (5 mcg/kg single daily dose)
Number of subjects: 120

Group type: COMPARATOR
Intervention: SC G‐CSF (filgrastim)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IV G‐CSF
Number of subjects: 120

Group type: COMPARATOR
Intervention: SC G‐CSF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both IV and SC G‐CSF
Number of subjects: 120
Study: 22864282

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg q.d.)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg b.i.d.)
Number of subjects: 471
Study: 19115106

Group type: EXPERIMENTAL
Intervention: 2nd-line hormone therapy
Number of subjects: 224
Study: 17661962

Group type: EXPERIMENTAL
Intervention: Educational intervention (mailing an antibiotic guide and prescribing profile)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Educational intervention (postintervention II)
Number of subjects: 36
Study: 15953681

Group type: EXPERIMENTAL
Intervention: Plasma (colloid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gelofusine (colloid)
Number of subjects: 20
Study: 12381426

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 391

Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 391
Study: 9987516

Group type: EXPERIMENTAL
Intervention: Dietary guidance alone (Regimen I)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dietary guidance plus the eating of wheat bran biscuits (Regimen II)
Number of subjects: 200
Study: 7750667

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2081866

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 135
Study: 582985

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg in customary preparation (A 300)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg in slow-release preparation (A ret)
Number of subjects: 5
Study: 31350643

Group type: EXPERIMENTAL
Intervention: SCEV group (n=39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group without visualization (n=39)
Number of subjects: 78
Study: 31058714

Group type: EXPERIMENTAL
Intervention: Trios-OSCE training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Regular OSCE training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (OSCE observers)
Number of subjects: 3
Study: 28586888

Group type: EXPERIMENTAL
Intervention: Community-based testing and treatment intervention
Number of subjects: 77774
Study: 25034118

Group type: EXPERIMENTAL
Intervention: Tyrosine/Phenylalanine depletion
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (balanced amino acid drink)
Number of subjects: 103
Study: 23486858

Group type: EXPERIMENTAL
Intervention: Trans-radial (TR) approach
Number of subjects: 1668

Group type: COMPARATOR
Intervention: Trans-femoral (TF) approach
Number of subjects: 1668
Study: 21843115

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of COPD
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Older patient age
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Higher numbers of comorbidities
Number of subjects: 445
Study: 19666358

Group type: EXPERIMENTAL
Intervention: Protocol A: Paracetamol suppository at a dose of 15 mg/kg
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Protocol B: Niflumique acid suppository at a dose of 13 mg/kg
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Protocol C: Combination of paracetamol (15 mg/kg) and niflumique acid (13 mg/kg)
Number of subjects: 202
Study: 16170976

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride gel‐releasing interdental brush (IDB)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard flossing regimen (positive control)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard tooth brushing only regimen (control)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Other IDB groups (not specified)
Number of subjects: 162
Study: 11836799

Group type: EXPERIMENTAL
Intervention: Aerobic training (5 sessions of 30-min duration per week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training (exercising upper and lower limbs against a graded resistance machine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard chest physiotherapy)
Number of subjects: 0
Study: 10530266

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral ibuprofen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7727330

Group type: COMPARATOR
Intervention: Clonidine 0 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 75 micrograms
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 60
Study: 2252045

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 21738

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21738
Study: 7017177

Group type: EXPERIMENTAL
Intervention: Oral levodopa and benserazide
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31712331

Group type: EXPERIMENTAL
Intervention: Neurosurgical ERAS protocol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Conventional perioperative care (control group)
Number of subjects: 140
Study: 28483221

Group type: EXPERIMENTAL
Intervention: Experimental external nasal dilator (END)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo external nasal dilator (END)
Number of subjects: 65
Study: 24832461

Group type: EXPERIMENTAL
Intervention: Bleeding within 30 days after PCI
Number of subjects: 14180

Group type: COMPARATOR
Intervention: No bleeding within 30 days after PCI
Number of subjects: 14180

Group type: EXPERIMENTAL
Intervention: Bleeding between 30 days to 1 year after PCI
Number of subjects: 14180

Group type: COMPARATOR
Intervention: No bleeding between 30 days to 1 year after PCI
Number of subjects: 14180
Study: 21118900

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 3354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3354
Study: 19824560

Group type: EXPERIMENTAL
Intervention: Grandio bonded with Solobond (n=36)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetric Ceram bonded with Syntac (n=32)
Number of subjects: 30
Study: 16739327

Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy (6x10(6) I.U. twice daily for 3 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no IL-2 treatment)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy in Dukes' B patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group for Dukes' B patients
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Pre-operative IL-2 immunotherapy in Dukes' C patients
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group for Dukes' C patients
Number of subjects: 86
Study: 15616339

Group type: EXPERIMENTAL
Intervention: MAALOX TC
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 2
Study: 12387773

Group type: EXPERIMENTAL
Intervention: Metronidazole (groups A and C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IBS treatment (groups B and D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole (groups C and D)
Number of subjects: 100
Study: 10420108

Group type: EXPERIMENTAL
Intervention: Eye gel containing calf blood extract
Number of subjects: 54

Group type: COMPARATOR
Intervention: Eye ointment containing vitamin A and dexpanthenol
Number of subjects: 54
Study: 8585042

Group type: EXPERIMENTAL
Intervention: Discontinuation of thromboprophylaxis one week after surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thromboprophylaxis
Number of subjects: 0
Study: 2247864

Group type: EXPERIMENTAL
Intervention: 2 mg beclomethasone dipropionate via metered dose inhaler alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg beclomethasone dipropionate via metered dose inhaler with a 750 ml spacing device
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 6895513

Group type: EXPERIMENTAL
Intervention: DSIP (delta sleep-inducing peptide)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31859911

Group type: EXPERIMENTAL
Intervention: CSII + Lira
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSII
Number of subjects: 60
Study: 31922512

Group type: EXPERIMENTAL
Intervention: Holisal gel applied 4 times a day in the socket
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard technique with the use of iodoform gauze
Number of subjects: 30
Study: 28010936

Group type: EXPERIMENTAL
Intervention: 30‐min distal cuff occlusion intervention (75 mmHg) at sea level
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30‐min distal cuff occlusion intervention (75 mmHg) at high altitude
Number of subjects: 12
Study: 25737484

Group type: EXPERIMENTAL
Intervention: HEART Pathway
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282
Study: 24405734

Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (IHD)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemofiltration (CVVH)
Number of subjects: 252
Study: 22798329

Group type: EXPERIMENTAL
Intervention: Mental imagery training combined with electromyogram‐triggered electric stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Generalized functional electric stimulation
Number of subjects: 14
Study: 19358783

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 395
Study: 17051405

Group type: EXPERIMENTAL
Intervention: CEE/MPA (estrogen + 2.5 mg medroxyprogesterone acetate)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: E2/NETA (1 mg 17 beta estradiol + 0.5 mg norethindrone acetate)
Number of subjects: 246
Study: 15207399

Group type: EXPERIMENTAL
Intervention: E. senticosus dry extract 300 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11773815

Group type: EXPERIMENTAL
Intervention: 1 mg of morphine with 75 microg of clonidine (Group M)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 12.5 mg of bupivacaine with 75 microg of clonidine (Group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (M and B)
Number of subjects: 36
Study: 9839098

Group type: EXPERIMENTAL
Intervention: Strict target level of glycemic control (fasting capillary glucose < 6.5 mmol/l)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Decrease in HbA1c of 1% or more
Number of subjects: 176

Group type: COMPARATOR
Intervention: Less strict target level of glycemic control (fasting capillary glucose < 8.5 mmol/l)
Number of subjects: 176
Study: 8076623

Group type: EXPERIMENTAL
Intervention: 2-chloropropionate (2-CP) 43 mg.kg-1 body mass
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2-chloropropionate (2-CP)
Number of subjects: 6
Study: 2634922

Group type: EXPERIMENTAL
Intervention: 0.5 mg. of PGE2 in 2 ml of tylose gel intracervically (group A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: 3.0 mg. of PGE2 in 5 ml of tylose gel intravaginally (group B)
Number of subjects: 106
Study: 1103606

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study: 30216378

Group type: EXPERIMENTAL
Intervention: Hepatic artery HMP (n = 10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-oxygen-supplemented portal vein HMP (n = 8)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxygen-supplemented portal vein HMP (n = 11)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Static cold storage (n = 7)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-transplantable livers
Number of subjects: 45
Study: 27157028

Group type: EXPERIMENTAL
Intervention: Challenging Horizons After School Program
Number of subjects: 112
Study: 24504937

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6160
Study: 22325984

Group type: EXPERIMENTAL
Intervention: LESS-RN
Number of subjects: 66

Group type: COMPARATOR
Intervention: LRN
Number of subjects: 66
Study: 20368393

Group type: EXPERIMENTAL
Intervention: 40 mg laninamivir octanoate
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 20 mg laninamivir octanoate
Number of subjects: 184

Group type: COMPARATOR
Intervention: oseltamivir
Number of subjects: 184
Study: 18584478

Group type: EXPERIMENTAL
Intervention: Very low fat diet (15% of calories from fat, N = 218)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Usual diet (30% of calories from fat, N = 332)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Very low fat diet (15% of calories from fat)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Usual diet (30% of calories from fat)
Number of subjects: 550
Study: 16150200

Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule (XST), 2 capsules orally, twice a day for 8 weeks.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Conventional Western medicines (mannitol, troxerutin, citicoline, piracetam, aspirin)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 204
Study: 12581252

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin (BT) injected by endoscopy in the lower esophageal sphincter (LES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline injected by endoscopy in the lower esophageal sphincter (LES)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Botulinum Toxin (BT)
Number of subjects: 24
Study: 10367822

Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg/kg in fruit juice
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral methionine, 100 mg/kg in fruit juice plus antioxidant vitamin E, 800 IU, and ascorbic acid, 1000 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methionine-free fruit juice (placebo)
Number of subjects: 20
Study: 8554933

Group type: EXPERIMENTAL
Intervention: Salbutamol 4 mg orally in CF patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Salbutamol 4 mg orally in healthy controls
Number of subjects: 11
Study: 2047051

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard wound management protocol without aloe vera gel
Number of subjects: 21
Study: 6117537

Group type: EXPERIMENTAL
Intervention: 3 mg lorazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg clobazam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29657137

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27084863

Group type: EXPERIMENTAL
Intervention: Modified dentoalveolar distractor
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 7
Study: 24952577

Group type: EXPERIMENTAL
Intervention: Standard PCV chemotherapy (procarbazine, CCNU, and vincristine)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard temozolomide (TMZ) 5-day schedule (200 mg/m2/day)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard temozolomide (TMZ) 21-day schedule (100 mg/m2/day)
Number of subjects: 447
Study: 22265810

Group type: EXPERIMENTAL
Intervention: Short message service (SMS) and Internet intervention for 12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study: 20502468

Group type: EXPERIMENTAL
Intervention: Vinegar added to a high-glycaemic index meal (mashed potatoes and low-fat milk)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (high-glycaemic index meal without vinegar)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vinegar added to a low-glycaemic index meal (whole grain bread, lettuce, and low-fat cheese)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (low-glycaemic index meal without vinegar)
Number of subjects: 16
Study: 19196930

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (14 infusions)
Number of subjects: 56
Study: 16210721

Group type: EXPERIMENTAL
Intervention: Highest quintile of n-3 fatty acids (FAs) intake
Number of subjects: 32470

Group type: EXPERIMENTAL
Intervention: Higher ratio of n-6 to n-3 FAs (>15:1)
Number of subjects: 32470

Group type: EXPERIMENTAL
Intervention: Tuna consumption (2-4 servings/week)
Number of subjects: 32470

Group type: EXPERIMENTAL
Intervention: Tuna consumption (5-6 servings/week)
Number of subjects: 32470
Study: 11841402

Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim) administered from 48 hours after completing chemotherapy until absolute neutrophil count exceeded 1.5 x 10(9)/l
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (no G‐CSF unless severe infection occurred)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: G‐CSF (Filgrastim)
Number of subjects: 270
Study: 10735895

Group type: EXPERIMENTAL
Intervention: Temozolomide (TEM) 200 mg/m²/d orally for 5 days every 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) 250 mg/m²/d IV for 5 days every 21 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of TEM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cost-effectiveness of DTIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations of CE threshold
Number of subjects: 0
Study: 9176076

Group type: EXPERIMENTAL
Intervention: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Short chain fatty acid (SCFA) rectal irrigation, twice daily for six weeks in patients with a short episode of colitis (< 6 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo treatment in patients with a short episode of colitis (< 6 months)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Open-label SCFA treatment after the controlled trial
Number of subjects: 103
Study: 1414149

Group type: EXPERIMENTAL
Intervention: beta‐interferon (1,000,000 IU)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: thymopentin (50 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 16
Study: 3551894

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g in a single oral dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 40
Study: 30690578

Group type: COMPARATOR
Intervention: COMBO
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 78